The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2016Defining Structural Forms of Alpha-synuclein Responsible for Key Features Associated with Parkinson's Disease
Study Rationale:
The alpha-synuclein pre-formed fibril (PFF) model shows promise for modeling many features of Parkinson’s disease (PD). In this model, PFFs induce pathological features and behaviors... -
Research Grant, 2016Therapeutic Effects of XPro1595 on Motor and Non-motor Outcomes in a Pre-clinical Model of Parkinson's disease
Study Rationale:
Studies funded under the 2012 TDI award revealed that peripheral administration of XPro1595 in the 6-OHDA (neurotoxin) pre-clinical model afforded significant neuroprotection against... -
Improved Biomarkers and Clinical Outcome Measures, 2016Defining a Parkinson's Disease-specific Breath Fingerprint of Inflammatory and Neurodegenerative Processes
Study Rationale:
Breath analysis has the potential to be a powerful non-invasive screening tool to help a clinician determine the need for additional tests, a tool for routine interval screening of... -
Research Grant, 2016LRRK2 Function in Immunity
Study Rationale:
LRRK2 is expressed in immune cells but its function in these cells is unknown. It is also not known whether mutations (such as G2019S) in LRRK2 that cause familial (inherited)... -
LRRK2 Therapeutic and Safety Initiative, 2016Evaluation of LRRK2 Inhibition in a Pre-clinical Model of Parkinson's Disease
Study Rationale:
The most common genetic cause of Parkinson's disease (PD) is mutations in the LRRK2 gene. Variations in the LRRK2 gene are associated with non-genetic PD as well. New drugs are being...
-
Oligomeric & pS129 Assay LEAPS, 2017Quantification of S129 Phosphorylated Alpha-synuclein Using the AlphaLISA® Immunoassay Platform
Study Rationale:
The alpha-synuclein protein is a key player in Parkinson’s disease (PD). Our ability to understand how this protein impacts the health of neurons in the brain is directly related to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.